Novartis AG 2012 AR2
The report highlights Novartis' performance in 2012, delivering net sales of USD 56.7 billion, with recently launched products contributing 29% of the total. The company invested over USD 9 billion in research and development, securing 17 major approvals across its portfolio, including Flucelvax and Bexsero. In corporate responsibility, Novartis provided healthcare access programs to over 100 million patients, valued at USD 2 billion. Additionally, the company achieved its 2012 Kyoto greenhouse gas emissions target through energy efficiency improvements and forestry carbon-offset projects.
Company: Novartis AG
Sector: Manufacturing
Country: Switzerland
Year: 2012
Type: AR2
Pages: 284
Back to company
Novartis AG
Annual Report
The report highlights Novartis' performance in 2012, delivering net sales of USD 56.7 billion, with recently launched products contributing 29% of the total. The company invested over USD 9 billion in research and development, securing 17 major approvals across its portfolio, including Flucelvax and Bexsero. In corporate responsibility, Novartis provided healthcare access programs to over 100 million patients, valued at USD 2 billion. Additionally, the company achieved its 2012 Kyoto greenhouse gas emissions target through energy efficiency improvements and forestry carbon-offset projects.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2012
Reporting Period
Jan 1, 2012 - Dec 31, 2012
Fiscal Year
2012
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Employees